ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

Core Viewpoint - ADMA Biologics, Inc. has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, reflecting the company's strong financial position and confidence in long-term growth [1][2]. Financial Initiatives - The capital return initiative includes an accelerated share repurchase (ASR) agreement where ADMA will pay JPMorgan $125 million upfront and receive about 6.4 million shares, representing approximately 80% of the expected repurchases based on a share price of $15.57 as of February 27, 2026 [2]. - The total number of shares repurchased will depend on the average daily volume-weighted price during the ASR term, and the completion is expected within five months [2]. - ADMA has a total of $500 million authorized for share repurchases under its existing program, and it plans to be opportunistic in executing these repurchases throughout 2026 [3]. Historical Context - Since the authorization of the share repurchase program in May 2025, ADMA has repurchased approximately $160 million of its common stock, demonstrating a disciplined approach to capital allocation [4]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [5]. - The company currently markets three FDA-approved plasma-derived biologics and is developing a pre-clinical hyperimmune globulin [5]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [5].